SBA Loans and Paycheck Protection Program (PPP) loans for practices impacted by the coronavirus pandemic are among the options addressed in a new video series, “Coping with COVID-19.” Eli Lilly and Company's Taltz is now approved to manage moderate to severe plaque psoriasis in pediatric patients ages 6 to under 18. LEO Pharma’s Finacea Foam (azelaic acid 15%) is back in pharmacies—just in time for Rosacea Awareness Month.
In a major reversal, the latest psoriasis guidelines recommend against yearly tuberculosis testing for psoriasis patients on biologics who are at low or no risk for TB, says Jashin J. Wu, MD. He also sheds light on studies comparing the 11 biologics that are currently approved for the treatment of psoriasis.
With more experience using IL-23 inhibitors to treat psoriasis, dermatologists are seeing high levels of patient satisfaction and no new safety signals. Jennifer Cather, MD assesses the clinical experience.
Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditions that increase risk for a severe course of COVID-19 including diabetes, hypertension, or liver disease.
Ask Dr. Friedman
Not many topical formulations tout benefits for psoriasis, but that doesn't mean there are no useful products. Dr. Friedman offers his take.
Adam Friedman, MD, FAAD
New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasis
Phase 3 Study Finds Twice-Weekly Enstilar Foam Safe and Effective for Long-Term Maintenance Treatment of Plaque Psoriasis
Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AAD
Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weeks
Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumab
DermWire TV: Kysse Approved, Sunscreen Use Trends, AbbVie/Allergan Deal
Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseases
In a major reversal, the latest psoriasis guidelines recommend against yearly tuberculosis testing for psoriasis patients on biologics who are at low...
Jashin J. Wu, MD, FAAD
With more experience using IL-23 inhibitors to treat psoriasis, dermatologists are seeing high levels of patient satisfaction and no new safety...
Jennifer Cather, MD